Type 2 DiabetesGLP-1inT2DNCT01977833
Meal Timing on Postprandial Glucose, Insulin and GLP-1 in Type 2 Diabetes
A study testing High Calorie Breakfast (BTdiet) and High Caloric Dinner (DTdiet) in people with Type 2 Diabetes, run by Tel Aviv University at 1 site in Israel.
Trial summary
Enhanced insulin and GLP-1 postprandial response after morning meal versus evening meal, might be underlying explanation of the beneficial effect of eating breakfast with reduced dinner vs skipping breakfast on glycemic control and HbA1c in T2D patients. Read more about this study
- Who is it for?
- Ages 30 to 70 years
- Conditions the study is for
- Type 2 Diabetes
- What is being tested?
- High Calorie Breakfast (BTdiet) and High Caloric Dinner (DTdiet)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteIsrael
- Study dates
- Oct 2013to Jan 2014
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Type 2 diabetes patients
- HbA1C > 7%
- Duration of diabetes: 0.5 to 10 years
- Subjects ≥ 30 and ≤70 years of age
- BMI: 22 to 35 kg/m2
- Diet controlled diabetic. Only treatment with metformin will be allowed
Show all 14Show fewer
- Normal liver and kidney function
- Normal thyroid function
- Acceptable health beside diabetes based on interview, medical history, physical examination, and laboratory tests
- Stable physical activity pattern during the three months immediately preceding study
- Usually wakes up between 06:00 and 07:00 and goes to sleep between 22:00 and 24:00.
- No shift work within 5 years of the study
- Did not cross time zones within 1 month of the study
- Read and understood the informed consent form and signed it voluntarily
Who cannot join
- Type 1 diabetes
- Clinically significant pulmonary, cardiac, renal, hepatic, neurologic, psychiatric, infectious, malignant disease
- Abnormal liver function tests defined as an increase by a factor of at least 2 above the upper normal limit of alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST)
- Pregnancy or lactation
- Illicit drug abuse or alcoholism
- Treatment with antidiabetic drugs, insulin or GLP-1 analogs
Show all 10Show fewer
- Subjects taking anoretic drugs during the month immediately prior to study
- Subjects on steroid treatment
- Those with eating disorders
- Subjects after bariatric surgery, will be excluded
Trial locations and contacts
1 site in 1 country.
Israel1 site, 1 recruiting
- Recruiting
Diabetes Unit E. Wolfson Medical center
Holon, Tel Aviv, 58100
Daniela Jakubowicz, MD, 972508105552, daniela.jak@gmail.com
Julio Wainstein, MD, 97254522296, vainstein@wolfson.health.gov.il
About this study
Official title: Effects of Meal Timing on Postprandial Glucose, Insulin and GLP-1 Responses After Breakfast Lunch and Dinner in Patients With Type 2 Diabetes
Enhanced insulin and GLP-1 postprandial response after morning meal versus evening meal, might be underlying explanation of the beneficial effect of eating breakfast with reduced dinner vs skipping breakfast on glycemic control and HbA1c in T2D patients.
To test this hypothesis and clarify whether glucose, insulin and GLP-1 postprandial responses are different in the morning vs. in the afternoon, the investigators will compare in T2D subjects in random order and in two separate days: the glucose, insulin and GLP-1 postprandial responses after breakfast, lunch and dinner with 2 isocaloric meal plans or test diets, that differ in meal timing distribution The investigators hypothesize that GLP-1 and insulin response after high calorie breakfast will be higher in comparison to GLP-1 and insulin response after identical meal at evening
Read the detailed description
The endogenous circadian (24-h) timing system, synchronized by light/dark cycle in the master circadian clock in the suprachiasmatic nuclei and by meal timing in the peripheral clock genes; plays a significant role in regulating sleep/wake and feeding behavior, body weight as well as glucose and lipid metabolism.
Circadian misalignment, involving sleep/wake and meal timing schedules 12 h out of phase from their habitual times resulted in elevated blood pressure and increased postprandial glucose and insulin levels. Animal models of circadian misalignment specially breakfast skipping are associated with alteration in the expression pattern of clock genes such as Clock, Bmal1, Cry1, and Per2 in the liver and fat cells. These changes resulted in a predisposition to obesity and type 2 diabetes (T2D). This may also explain why evening or night eating is often associated with weight gain and obesity.
Breakfast skipping has been consistently associated with increased, visceral adiposity, higher BMI and waist circumference, insulin resistance, dyslipidemia and with T2D despite having less total daily caloric intake.
A recent population-based studies have found that participants with an evening preferences (late chronotype) that involves breakfast skipping, have 2.5 times risk of developing T2D, even after adjustment for body mass index (BMI) (12).
Breakfast skipping and greater percentage of their daily caloric intake at dinner was associated with higher fasting plasma glucose levels, and poorer glycemic control compared with earlier chronotypes even after adjusting for BMI (11,20,21). Recently was documented that in T2D patients, breakfast skipping was associated was associated with a 10.8% increase in HbA1C of its original value, even after adjusting for age, sex, race, BMI, number of diabetes complications, insulin use, depressive symptoms, perceived sleep debt, and percentage of daily caloric intake at dinner. This significant difference in HbA1C levels between breakfast skippers and breakfast eaters in patients with T2D, highlights the potential impact of the meal timing on the course of the disease.
More recently the investigators documented that compared to a conventional diet, a high caloric intake in the breakfast and reduced dinner resulted in significant reduction of HbA1c in T2D individuals.
The existence of diurnal variation in glucose tolerance in healthy and in subjects with T2D has been suspected for decades, with reports showing that glucose tolerance decreases progressively throughout the day with insulin sensitivity reaching a nadir in the evening. The reduction of glucose tolerance in the evening, seems to be a results from a combination of reduced glucose utilization, decreased insulin sensitivity, and inappropriately low insulin secretion and action, which highlights the importance of meal timing in glucose metabolism.
It is known that insulin response to meal ingestion is more rapid in the morning than in the afternoon and specifically the early (30 or 45 min) insulin secretion after oral glucose or meal ingestion is significantly higher in the morning than in the evening. A possible explanation for the more rapid glucose clearance from the circulation in the morning is because the early insulin response is important for rapid reduction in hepatic glucose output after meal ingestion.
Recently was shown that the enhanced early (30-min) insulin secretion after morning meal vs. afternoon, was accompanied by a correspondingly faster incretin total GLP-1 and intact GLP-1 hormone response in the morning specially during the first 30 min after ingestion. The association was consistent and also supports the prediction that higher GLP-1 levels after morning meal would result in a higher potentiation of β-cell function.
This diurnal pattern of enhanced insulin and GLP-1 response after morning meal versus in the evening, might be underlying explanation of the beneficial effect of eating breakfast with reduced dinner vs skipping breakfast on glycemic control and HbA1c in T2D patients.
To test this hypothesis the investigators will compare in random order and in two separate days: the glucose, insulin and GLP-1 postprandial responses after breakfast, lunch and dinner with 2 isocaloric meal plans or test diets, that differ only in meal timing distribution
- High caloric breakfast, average lunch and reduced dinner (BTdiet) and
- High caloric dinner, similar lunch and reduced breakfast (DTdiet)
- Conditions
- Type 2 Diabetes
- Being tested
- High Calorie Breakfast (BTdiet), High Caloric Dinner (DTdiet)
- Keywords
- BTdiet, Dtdiet, High Calorie Breakfast diet (BTdiet), High Calorie Dinner diet (DTdiet)
- Medical subject headings
- Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
High Calorie Breakfast (BTdiet)Other
High Caloric Breakfast Test Diet (BTdiet): in which the majority of energy load will be consumed in the morning and with reduced dinner
High Caloric Dinner (DTdiet)Other
High Caloric Dinner (DTdiet): resembling a skipping breakfast plan, in which the majority of energy load will be consumed in the evening with minimal caloric content at breakfast
| Study group | Role | What they receive |
|---|---|---|
| High Calorie Breakfast (BTdiet) | Experimental | High Calorie Breakfast (BTdiet): The subject will consume High caloric breakfast, average lunch and reduced in calories dinner (BTdiet) Receives: Other: High Calorie Breakfast (BTdiet) |
| High Calorie Dinner (DTdiet) | Active comparator | High Calorie Dinner (DTdiet): The subject will consume High caloric dinner, average lunch and reduced in calories breakfast (DTdiet) Receives: Other: High Caloric Dinner (DTdiet) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Postprandial GLP-1 plasma levels, after breakfast,lunch and dinner meal test
All Type 2 diabetic participants will be randomly assigned to one of 2 isocaloric diet sequences that will differ in the meal timing distribution. The diets will be tested in two separate occasions during a curse of a single day (test day) in which postprandial plasma GLP-1 levels during 3 hours after breakfast, lunch and dinner meal challenge will be measured
Measured: During 3 hours after breakfast, lunch and dinner meal challange
Secondary outcomes (1)
Postprandial Plasma Glucose levels after breakfast, lunch and dinner meal challenge
All Type 2 diabetic participants will be randomly assigned to one of 2 isocaloric diet sequences that will differ in the meal timing distribution. The diets will be tested in two separate occasions during a curse of a single day (test day) in which postprandial plasma Glucose levels during 3 hours after breakfast, lunch and dinner meal challenge will be measured
Measured: Postprandial Plasma Glucose levels during 3 hours after breakfast, lunch and dinner meal challenge
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Nov 2013 (estimated)
- Study startOct 2013
- Primary completionDec 2013 (estimated)
- Study completionJan 2014 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Type 2 DiabetesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Tel Aviv University
- Sponsor type
- University, hospital or other
- Collaborators
- Wolfson Medical Center
- Responsible party
- Principal investigator, Daniela Jakubowicz, Tel Aviv University
- Investigators
- Daniela Jakubowicz, Principal investigator, E. Wolfson Medical Center. Tel Aviv University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01977833
- Sponsor's protocol ID
- 0145-13-WOMC
- Acronym
- GLP-1inT2D
- Status last verified
- Oct 2013
- First submitted
- 31 Oct 2013
- Last updated
- 7 Nov 2013
- Results posted
- No
- Data monitoring committee
- No
Publications
Jakubowicz D, Wainstein J, Ahren B, Bar-Dayan Y, Landau Z, Rabinovitz HR, Froy O. High-energy breakfast with low-energy dinner decreases overall daily hyperglycaemia in type 2 diabetic patients: a randomised clinical trial. Diabetologia. 2015 May;58(5):912-9. doi: 10.1007/s00125-015-3524-9. Epub 2015 Mar 1.
PubMed 25724569
Study at a glance
From the registry record, last updated by the sponsor on 7 Nov 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Meal Timing on Postprandial Glucose, Insulin and GLP-1 Responses After Breakfast Lunch and Dinner in Patients With Type 2 Diabetes
- ClinicalTrials.gov ID
- NCT01977833
- Acronym / sponsor ID
- GLP-1inT2D / 0145-13-WOMC
- Conditions
- Type 2 Diabetes
- Keywords
- BTdiet, Dtdiet, High Calorie Breakfast diet (BTdiet), High Calorie Dinner diet (DTdiet)
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Tel Aviv UniversityUniversity, hospital or other
- Collaborators
- Wolfson Medical Center
- Study start
- Oct 2013
- Primary completion
- Dec 2013 (estimated)
- Study completion
- Jan 2014 (estimated)
- First posted
- 7 Nov 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Enhanced insulin and GLP-1 postprandial response after morning meal versus evening meal, might be underlying explanation of the beneficial effect of eating breakfast with reduced dinner vs skipping breakfast on glycemic control and HbA1c in T2D patients.
To test this hypothesis and clarify whether glucose, insulin and GLP-1 postprandial responses are different in the morning vs. in the afternoon, the investigators will compare in T2D subjects in random order and in two separate days: the glucose, insulin and GLP-1 postprandial responses after breakfast, lunch and dinner with 2 isocaloric meal plans or test diets, that differ in meal timing distribution The investigators hypothesize that GLP-1 and insulin response after high calorie breakfast will be higher in comparison to GLP-1 and insulin response after identical meal at evening
Detailed description
The endogenous circadian (24-h) timing system, synchronized by light/dark cycle in the master circadian clock in the suprachiasmatic nuclei and by meal timing in the peripheral clock genes; plays a significant role in regulating sleep/wake and feeding behavior, body weight as well as glucose and lipid metabolism.
Circadian misalignment, involving sleep/wake and meal timing schedules 12 h out of phase from their habitual times resulted in elevated blood pressure and increased postprandial glucose and insulin levels. Animal models of circadian misalignment specially breakfast skipping are associated with alteration in the expression pattern of clock genes such as Clock, Bmal1, Cry1, and Per2 in the liver and fat cells. These changes resulted in a predisposition to obesity and type 2 diabetes (T2D). This may also explain why evening or night eating is often associated with weight gain and obesity.
Breakfast skipping has been consistently associated with increased, visceral adiposity, higher BMI and waist circumference, insulin resistance, dyslipidemia and with T2D despite having less total daily caloric intake.
A recent population-based studies have found that participants with an evening preferences (late chronotype) that involves breakfast skipping, have 2.5 times risk of developing T2D, even after adjustment for body mass index (BMI) (12).
Breakfast skipping and greater percentage of their daily caloric intake at dinner was associated with higher fasting plasma glucose levels, and poorer glycemic control compared with earlier chronotypes even after adjusting for BMI (11,20,21). Recently was documented that in T2D patients, breakfast skipping was associated was associated with a 10.8% increase in HbA1C of its original value, even after adjusting for age, sex, race, BMI, number of diabetes complications, insulin use, depressive symptoms, perceived sleep debt, and percentage of daily caloric intake at dinner. This significant difference in HbA1C levels between breakfast skippers and breakfast eaters in patients with T2D, highlights the potential impact of the meal timing on the course of the disease.
More recently the investigators documented that compared to a conventional diet, a high caloric intake in the breakfast and reduced dinner resulted in significant reduction of HbA1c in T2D individuals.
The existence of diurnal variation in glucose tolerance in healthy and in subjects with T2D has been suspected for decades, with reports showing that glucose tolerance decreases progressively throughout the day with insulin sensitivity reaching a nadir in the evening. The reduction of glucose tolerance in the evening, seems to be a results from a combination of reduced glucose utilization, decreased insulin sensitivity, and inappropriately low insulin secretion and action, which highlights the importance of meal timing in glucose metabolism.
It is known that insulin response to meal ingestion is more rapid in the morning than in the afternoon and specifically the early (30 or 45 min) insulin secretion after oral glucose or meal ingestion is significantly higher in the morning than in the evening. A possible explanation for the more rapid glucose clearance from the circulation in the morning is because the early insulin response is important for rapid reduction in hepatic glucose output after meal ingestion.
Recently was shown that the enhanced early (30-min) insulin secretion after morning meal vs. afternoon, was accompanied by a correspondingly faster incretin total GLP-1 and intact GLP-1 hormone response in the morning specially during the first 30 min after ingestion. The association was consistent and also supports the prediction that higher GLP-1 levels after morning meal would result in a higher potentiation of β-cell function.
This diurnal pattern of enhanced insulin and GLP-1 response after morning meal versus in the evening, might be underlying explanation of the beneficial effect of eating breakfast with reduced dinner vs skipping breakfast on glycemic control and HbA1c in T2D patients.
To test this hypothesis the investigators will compare in random order and in two separate days: the glucose, insulin and GLP-1 postprandial responses after breakfast, lunch and dinner with 2 isocaloric meal plans or test diets, that differ only in meal timing distribution
- High caloric breakfast, average lunch and reduced dinner (BTdiet) and
- High caloric dinner, similar lunch and reduced breakfast (DTdiet)
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| High Calorie Breakfast (BTdiet) | Experimental | Other: High Calorie Breakfast (BTdiet)High Calorie Breakfast (BTdiet): The subject will consume High caloric breakfast, average lunch and reduced in calories dinner (BTdiet) |
| High Calorie Dinner (DTdiet) | Active comparator | Other: High Caloric Dinner (DTdiet)High Calorie Dinner (DTdiet): The subject will consume High caloric dinner, average lunch and reduced in calories breakfast (DTdiet) |
Who may qualify
- Ages
- 30 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (14 listed)
- Type 2 diabetes patients
- HbA1C > 7%
- Duration of diabetes: 0.5 to 10 years
- Subjects ≥ 30 and ≤70 years of age
- BMI: 22 to 35 kg/m2
Key exclusion criteria (10 listed)
- Type 1 diabetes
- Clinically significant pulmonary, cardiac, renal, hepatic, neurologic, psychiatric, infectious, malignant disease
- Abnormal liver function tests defined as an increase by a factor of at least 2 above the upper normal limit of alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST)
- Pregnancy or lactation
- Illicit drug abuse or alcoholism
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| High Calorie Breakfast (BTdiet)High Caloric Breakfast Test Diet (BTdiet): in which the majority of energy load will be consumed in the morning and with reduced dinner | Other | High Calorie Breakfast (BTdiet) |
| High Caloric Dinner (DTdiet)High Caloric Dinner (DTdiet): resembling a skipping breakfast plan, in which the majority of energy load will be consumed in the evening with minimal caloric content at breakfast | Other | High Calorie Dinner (DTdiet) |
Primary outcome
Postprandial GLP-1 plasma levels, after breakfast,lunch and dinner meal test
Time frame: During 3 hours after breakfast, lunch and dinner meal challange
All Type 2 diabetic participants will be randomly assigned to one of 2 isocaloric diet sequences that will differ in the meal timing distribution. The diets will be tested in two separate occasions during a curse of a single day (test day) in which postprandial plasma GLP-1 levels during 3 hours after breakfast, lunch and dinner meal challenge will be measured
1 secondary outcome
Postprandial Plasma Glucose levels after breakfast, lunch and dinner meal challenge
Time frame: Postprandial Plasma Glucose levels during 3 hours after breakfast, lunch and dinner meal challenge
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Nov 2013.
- Derived from this study: PubMed 25724569Jakubowicz D, Wainstein J, Ahren B, Bar-Dayan Y, Landau Z, Rabinovitz HR, Froy O. High-energy breakfast with low-energy dinner decreases overall daily hyperglycaemia in type 2 diabetic patients: a randomised clinical trial. Diabetologia. 2015 May;58(5):912-9. doi: 10.1007/s00125-015-3524-9. Epub 2015 Mar 1.
Related trials for Type 2 Diabetes
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Daniela Jakubowicz principal investigator
E. Wolfson Medical Center. Tel Aviv University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing High Calorie Breakfast (BTdiet) and High Caloric Dinner (DTdiet) in people with Type 2 Diabetes, run by Tel Aviv University at 1 site in Israel.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 14 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 7 Nov 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Daniela Jakubowicz, MD (972508105552, daniela.jak@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Postprandial GLP-1 plasma levels, after breakfast,lunch and dinner meal test (time frame: During 3 hours after breakfast, lunch and dinner meal challange). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01977833, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Nov 2013.